These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22609485)

  • 21. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant treatment for breast cancer in the elderly.
    Marchei P; Bianco V; Pignatelli E; Chiodini S; Santini D; Carico E; Marchei M; Vecchione A
    Anticancer Res; 1996; 16(2):911-3. PubMed ID: 8687150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of tamoxifen as treatment of breast cancer.
    Powles TJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-48-S1-54. PubMed ID: 9045315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen deprivation therapy and colon cancer risk in breast cancer patients.
    Malaka DO; Olopade OI
    Breast J; 2010; 16(1):110-2. PubMed ID: 19929891
    [No Abstract]   [Full Text] [Related]  

  • 26. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT; Andersen J
    Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Parikh RP; Odom EB; Yu L; Colditz GA; Myckatyn TM
    Breast Cancer Res Treat; 2017 May; 163(1):1-10. PubMed ID: 28185144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel algorithm to reduce VTE in peri-operative patients on tamoxifen.
    Nicola A; Crowley M; See M
    Breast; 2021 Aug; 58():88-92. PubMed ID: 33989964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venous thromboembolism prophylaxis for abdominal free tissue breast reconstruction: a multicenter survey.
    Gilleard O; Askouni E; Tavsanoglu Y; Jones ME
    J Plast Reconstr Aesthet Surg; 2014 May; 67(5):733-5. PubMed ID: 24388130
    [No Abstract]   [Full Text] [Related]  

  • 37. Tamoxifen and risk of idiopathic venous thromboembolism.
    Meier CR; Jick H
    Br J Clin Pharmacol; 1998 Jun; 45(6):608-12. PubMed ID: 9663819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience.
    Onitilo AA; Doi SA; Engel JM; Glurich I; Johnson J; Berg R
    Thromb Res; 2012 Jul; 130(1):27-31. PubMed ID: 22154240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis.
    Webster TK; Roth SC; Yu D; Baltodano PA; Araya S; Elmer NA; Kaplunov BS; Massada KE; Talemal L; Hackley M; Patel SA
    Breast Cancer Res Treat; 2022 Jun; 193(2):241-251. PubMed ID: 35286525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perioperative Management of Female Hormone Medications.
    Seim LA; Irizarry-Alvarado JM
    Curr Clin Pharmacol; 2017; 12(3):188-193. PubMed ID: 28969534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.